scholarly journals Intensified electrical stimulation targeting lateral and medial prefrontal cortices for the treatment of social anxiety disorder: A randomized, double-blind, parallel-group, dose-comparison study

2021 ◽  
Author(s):  
Eisa Jafari ◽  
Jaber Alizadehgoradel ◽  
Fereshteh Pourmohseni Koluri ◽  
Ezzatollah Nikoozadehkordmirza ◽  
Meysam Refahi ◽  
...  
2002 ◽  
Vol 63 (1) ◽  
pp. 66-74 ◽  
Author(s):  
Michael R. Liebowitz ◽  
Murray B. Stein ◽  
Manuel Tancer ◽  
David Carpenter ◽  
Rosemary Oakes ◽  
...  

2004 ◽  
Vol 61 (11) ◽  
pp. 1153 ◽  
Author(s):  
Karen Dineen Wagner ◽  
Ray Berard ◽  
Murray B. Stein ◽  
Erica Wetherhold ◽  
David J. Carpenter ◽  
...  

2005 ◽  
Vol 186 (3) ◽  
pp. 222-226 ◽  
Author(s):  
Siegfried Kasper ◽  
Dan J. Stein ◽  
Henrik Loft ◽  
Rico Nil

BackgroundSelective serotonin reuptake inhibitors are effective in the treatment of social anxiety disorder and are currently regarded as the pharmacotherapy of choice.AimsTo investigate the efficacy and tolerability of escitalopram in the treatment of generalised social anxiety disorder.MethodPatients with generalised social anxiety disorder were randomised to receive placebo (n=177) or 10–20 mg escitalopram (n=181) in a 12-week, double-blind trial. The primary outcome measure was the mean change from baseline to last assessment in the Liebowitz Social Anxiety Scale (LSAS) total score.ResultsThe study showed a statistically superior therapeutic effect for escitalopram compared with placebo on the LSAS total score (P=0.005). There were significantly more responders to treatment for escitalopram than for placebo (54% v. 39%; P < 0.0 1). The clinical relevance of these findings was supported by significant reduction in the work and social components of the Sheehan Disability Scale and by the good tolerability of escitalopram treatment.ConclusionsEscitalopram was efficacious and well tolerated in the treatment of generalised social anxiety disorder.


2007 ◽  
Vol 85 (9) ◽  
pp. 928-932 ◽  
Author(s):  
Craig Hudson ◽  
Susan Hudson ◽  
Joan MacKenzie

Until recently, intact protein that is rich in tryptophan was not seen as an alternative to pharmaceutical-grade tryptophan because protein also contains large neutral amino acids (LNAAs) that compete for transport sites across the blood–brain barrier. Recent evidence indicates that when deoiled gourd seed (a rich source of tryptophan with approximately 22 mg/g protein) is combined with glucose (a carbohydrate that reduces serum levels of competing LNAAs) a clinical effect similar to that of pharmaceutical-grade tryptophan is achieved. Objective and subjective measures of anxiety in those suffering from social phobia (also known as social anxiety disorder) were employed to measure changes in anxiety in response to a stimulus as part of a double-blind, placebo-controlled, crossover study with a wash-out period of 1 week between study sessions. Subjects were randomly assigned to start with either (i) protein-source tryptophan (deoiled gourd seed) in combination with carbohydrate or (ii) carbohydrate alone. One week after the initial session, subjects returned for a follow-up session and received the opposite treatment of that received at the first session. All 7 subjects who began the study completed the 2-week protocol. Protein-source tryptophan with carbohydrate, but not carbohydrate alone, resulted in significant improvement on an objective measure of anxiety. Protein-source tryptophan combined with a high glycemic carbohydrate is a potential anxiolytic to those suffering from social phobia.


Sign in / Sign up

Export Citation Format

Share Document